Clinical Trials Sponsored by Spero Therapeutics

Total 6774 results

1
2
3
4
5
6
7
8
9
10
...
135
136
›

Spero Therapeutics

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

United States
Spero Therapeutics

Completed

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

Healthy Volunteer

United States
Spero Therapeutics

Completed

A Study to Compare Two Bioanalytical Assays for Tebipenem

Healthy Volunteers

United States
Spero Therapeutics

Completed

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO)

Acute Pyelonephritis | Complicated Urinary Tract Infection

Bulgaria, Georgia, United States, Czechia, Estonia, Hungary, Latvia, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Ukraine
Spero Therapeutics

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Mycobacterium Avium Complex | Non-tuberculous Mycobacterium Pulmonary Disease

United States
Spero Therapeutics

Completed

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Renal Impairment

United States
Spero Therapeutics

Completed

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Healthy Volunteers

United States
Spero Therapeutics

Completed

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

Healthy Volunteers

United States
Spero Therapeutics

Completed

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Healthy Volunteers

United States
Spero Therapeutics
Clinartis

Completed

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

Healthy Volunteers

United States
Spero Therapeutics
Celerion

Completed

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

TQT Study

United States
Spero Therapeutics
GlaxoSmithKline

Recruiting

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

Healthy Participants

United States
Spero Therapeutics
GlaxoSmithKline

Recruiting

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO)

Urinary Tract Infection | Acute Pyelonephritis

Moldova, Republic of, Georgia, United States, Serbia, Bulgaria, Romania, South Africa, Bosnia and Herzegovina, Croatia, Hungary, Poland, Slovakia, Estonia, Argentina, Turkey, Brazil, Greece, India, Latvia
Spero Therapeutics
Covance

Completed

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

Healthy Volunteers

United States
Hartford Hospital
Spero Therapeutics

Completed

Bioavailability of Tebipenem (SPR994) Crushed Tablet

Relative Bioavailability

United States
Hartford Hospital
Spero Therapeutics

Completed

Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Diabetes | ABSSSI | Healthy Volunteers | Wound Infection

United States
Spero Therapeutics
Simbec Research

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Spero Therapeutics
Iqvia Pty Ltd

Completed

Effect of Tebipenem on Normal Human Intestinal Microbiota

Healthy Volunteers

Sweden
Spero Therapeutics
United States Department of Defense

Completed

Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Spero Therapeutics
Simbec Research; QPS Holdings LLC

Completed

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

Healthy Volunteers

United Kingdom
Spero Therapeutics
United States Department of Defense

Completed

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

Renal Impairment

New Zealand
Spero Therapeutics
CPR Pharma Services Pty Ltd, Australia

Completed

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers

Healthy Volunteers

Australia
Spero Therapeutics
Clinical Network Services (CNS) Pty Ltd

Completed

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers

Healthy Volunteers

Australia
Spero Therapeutics
CPR Pharma Services Pty Ltd, Australia

Completed

Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994

Healthy Volunteers

Australia
The Chemo-Sero-Therapeutic Research Institute

Completed

A Study of Anti-HIV Monoclonal Antibody KD-247

HIV Infections

United States
Espero Biopharma

Unknown

Tecarfarin Anti-Coagulation Trial (TACT) (TACT)

Thrombosis | Thromboembolism
Stero Biotechs Ltd.

Terminated

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Autoimmune Hepatitis

Israel
Stero Biotechs Ltd.

Completed

Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients

Chronic Spontaneous Urticaria

Israel
Stero Biotechs Ltd.

Completed

A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients

Steroid Dependent Crohn's Disease

Israel
Aspero Medical, Inc.
National Institutes of Health (NIH)

Recruiting

Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Small Bowel Disease

United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

China, United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation (TRIAD1)

KRAS G12D Mutation

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Terminated

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Terminated

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
Innoviva Specialty Therapeutics
Entasis Therapeutics

Not yet recruiting

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

United States
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, Korea, Republic of, United States, China
CRISPR Therapeutics AG

Terminated

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States, Australia
CRISPR Therapeutics AG

Terminated

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States, Australia, Canada, Germany
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
CRISPR Therapeutics AG
ViaCyte

Recruiting

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Melinta Therapeutics, LLC

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Gram Positive Bacterial Infections

United States

1
2
3
4
5
6
7
8
9
10
...
135
136
›

3

Subscribe